Sotorasibu China launch time forecast and drug purchase guide

Sotorasib, this innovative drug for patients with advanced non-small cell lung cancer (NSCLC) carrying KRAS G12C mutations, has been attracting the attention of domestic patients since it was approved in 2021 in the United States, the European Union and other places. However, because new drugs need to go through a series of complex approval processes to enter the Chinese market, sotorasibu has not yet been officially launched in China, resulting in many patients being unable to obtain this life-saving drug through formal domestic channels.

KRAS G12C mutation is quite common in lung cancer patients, but for a long time, there have been few effective targeted drugs for this mutation. As the first approved KRAS G12C inhibitor, sotoracib has brought new hope to countless Chinese patients carrying such mutations. So, when will Sotorasibu be available in China?

It is understood that new foreign drugs entering the Chinese market need to go through multiple links such as clinical trials, drug approval and document review. At present, the clinical trial data collection of sotorasibu in China is nearing completion, which indicates that its application for marketing process may make breakthrough progress in the next one to two years. The National Medical Products Administration (NMPA) will flexibly adjust the approval speed of sotoraxib based on trial data and patient needs. If all goes well, domestic patients are expected to be able to purchase this innovative drug through formal channels in the near future.

In addition, China is continuously increasing its efforts to include innovative drugs in the medical insurance catalog. Once sotorasibu is launched in China, if it can successfully enter the national medical insurance directory, it will greatly reduce the financial burden on patients. However, the inclusion of drugs in medical insurance needs to go through a strict negotiation process. Taking into account various factors such as drug prices, efficacy, and actual patient needs, this process may be relatively lengthy. Therefore, even after sotoracib is launched, patients still need to wait patiently for the good news that it will be included in medical insurance.

Under the current circumstances, if domestic patients urgently need sotoraxib, they can obtain generic drugs from Laos and other places through overseas channels. These generic drugs are similar in active ingredients to the brand-name drugs and provide patients with a temporary solution. In the next one to two years, if sotoracib can be successfully launched in China, it will provide patients with a more convenient and compliant drug purchase channel, allowing more people to enjoy the benefits of this innovative drug.